Oral delivery of proteins and peptides has historically faced significant technical barriers due to the enzymatic degradation and poor permeability of macromolecules in the gastrointestinal (GI) tract ...

By packaging one in pill form ... one can get quickly dissolved in the stomach before it has a chance to act. Rybelsus, semaglutide-maker Novo Nordisk's GLP-1 pill, brute forces its way around ...

Some doctors also report that Rybelsus may not be as effective as injections yet ... They need to be refrigerated and require plastic applications, whereas pills have less packaging. “Drugs in tablet ...

Researchers at Virginia Tech have found a way to make biodegradable packaging stronger while using less energy in the process. The research team from the College of Agriculture and Life Sciences ...

When 2025 began, packaging experts agreed that the number one trend in their industry this year would be sustainable materials, ranging from biodegradable and compostable packaging to eco-friendly ...

SEMAGLUTIDE, sold under the brand names Ozempic, Wegovy and Rybelsus, is a drug originally ... way to identify if a product is genuine or not. Packaging on counterfeit medication can appear ...

April 2 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) Novo Nordisk’s (NOVOb.CO), opens new tab diabetes medicine Rybelsus, an oral form of the GLP-1 drug ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease. Results from ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...

Rybelsus reduced the risk of major cardiovascular events by 14% in high-risk patients. Get 5 ‘Hidden Gem’ stock picks and daily rankings—now 60% off for Memorial Day. Novo Nordisk A/S NVO on ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the ...